Clinical trialPhase 1Completed
Multiple Ascending Dose (MDX1105-01)
A Phase 1, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- February 2009
- Expected end
- July 2015
- Enrollment
- 281 participants
- Sites
- 11
- Primary outcomes
- Safety, maximum tolerated dose (MTD) and dose-limiting toxicity(DLT)of MDX-1105; Safety, maximum tolerated dose (MTD) and dose-limiting toxicity(DLT)of MDX-1105
- Sponsor
- Industry
- Results posted
- No
- Last update
- 7 September 2015
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.
Detailed description public domain (ClinicalTrials.gov)
This is an open label, multicenter, dose escalation and multidose study of MDX-11-5, a fully human monoclonal IgG4 antibody targeting the Programed Death-Ligand 1 (PD-L1). The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 16 six-week cycles), and Follow-up (up to 6 months).